BRISTOL PRAVACHOL SALES SPURRED BY DTC CAMPAIGN; SB's HAVRIX BREAKS VACCINE TREND WITH 18% RISE; FTC DOES NOT OBJECT TO MCKESSON PURCHASE OF FOXMEYER
Executive Summary
Bristol-Myers Squibb's direct-to-consumer advertising campaign for Pravachol "spurred" a 35% sales increase for the HMG-CoA reductase inhibitor during the quarter, the company indicated. The cholesterol-lowering agent posted $261 mil. in sales for the quarter. Nine-month sales were up 38% to $767 mil.